Search 

AdVax is an inter/multi-disciplinary team of individuals who have developed major paradigm-shifting science, research, technology and new clinical data sets demonstrating previously unidentified bacterial infections are able to translocate to the brain and be linked to the induction of Alzheimer’s disease.

We have developed novel and proprietary real time molecular diagnostics to identify these non-culturable bacteria and then apply novel immune refocusing technologies to create both monoclonal antibodies that could be used in treatments and a first of its kind vaccine for the prevention of both cardiovascular and Alzheimer’s disease.

Our program is well on its way to identifying the major disease-inducing bacteria, which are then ready to be put into the immune refocusing technology for the derivation of human monoclonal antibodies and vaccines.

Advent Life Sciences

We invest predominantly in early and mid-stage life sciences companies.  We seek to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.

Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA.

Real people. Real insight. Real value.

Innovation. Clarity. Execution.

Altravax is a privately held biopharmaceutical company focused on developing first-in-class biological products to fight infectious diseases or treat other indications. The Company has a robust pipeline of candidates at various preclinical stages of development including a therapeutic vaccine against chronic hepatitis B infection. Altravax seeks investment opportunities to develop these lead candidates for clinical testing.

Antibody Solutions is a premier developer of therapeutic, diagnostic and critical reagent antibodies. Our platforms include human antibodies from transgenic OmniRats™, Hybridoma Libraries™, and high-throughput flow-cytometry screening of cell-associated targets. We provide full technical support and project management with all services performed in the USA. 

Aperiomics, Inc. is a next generation sequencing service company with a mission to detect virtually any pathogen from any clinical, agricultural, or environmental sample.  This service platform uses a combination of next-generation sequencing and advanced bioinformatic data analysis to identify pathogens in various samples.  Aperiomics’ proprietary service platform focuses on pathogens of public and animal health importance, satisfying the increasing need for more robust and more efficient next-generation sequencing data analysis.

The impact of Aperiomics’ technologies is broad due to our unique approach to pathogen detection. Instead of blindly probing for a proverbial ‘needle in a haystack’, Aperiomics’ approach analyzes the entire ‘haystack’ using next-generation sequencing and harnessing the power of bioinformatics to identify all ‘needles’. This approach is transformative compared to current pathogen detection methods. Aperiomics’ proprietary service, Absolute*NGS Pathogen Detection Platform, screens samples (clinical, environmental, etc.) for the presence of any microbe (fungal, viral, bacterial, eukaryotic parasite) – including pathogens that have never before been identified. This platform technology has broad application across diverse markets such as health care, agriculture, environmental, industrial, and veterinary testing.

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.